Optimizing treatment before surgery for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a neoadjuvant (before surgery) treatment plan for people with early-stage HER2-positive breast cancer. The goal is to see if a personalized approach can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast tumor is larger than 2 cm, or has spread to nearby lymph nodes.
- Your cancer is HER2-positive (a specific protein that promotes growth).
- You have not had chemotherapy, anti-HER2 therapy, or radiation for invasive breast cancer before.
- Your heart function is normal (left ventricular ejection fraction greater than 50%).
- You have adequate bone marrow, liver, and kidney function as shown by blood tests.
- You are able to have a breast MRI and provide blood samples for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests whether a customized treatment plan given before surgery can improve outcomes for women with early-stage HR-positive, HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
This trial compares two anti-HER2 medicines given before surgery to shrink HER2-positive early breast cancer. It aims to see which treatment works better as “neoadjuvant” therapy to improve outcomes while keeping you safe.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a personalized treatment plan for HER2-positive breast cancer before surgery. The treatment is adjusted based on how your cancer responds, aiming to give you the best possible outcome.
Hear when a new HER2-positive Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.